Immuno oncology

Immunotherapy Combination Is Active in Patients With Melanoma Brain Metastases
BY Jason M. Broderick
Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a response in some patients with melanoma brain metastases, according to a recent study presented at ASCO. 
Using a Virus to Boost Immunotherapy Response in Melanoma
BY Lauren M. Green
Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.
How I Remember
BY Diana M. Martin
A plan for remembering your loved one when times get tough.
FDA Approves Bavencio for Bladder Cancer
BY Jason M. Broderick
The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Tecentriq Approved as First-Line Treatment for Some Patients With Bladder Cancer
BY Jason Broderick
The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
With Immunotherapy, Longer Survival May Come With a Cost in Melanoma
BY Jason Harris
Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.
Opdivo Is Promising for Advanced Anal Cancer, Study Shows
BY Jason Harris
The PD-1 inhibitor, Opdivo, may be a promising option for patients with advanced anal cancer, according to a recent study. 
The Future of Immunotherapy for Urothelial Carcinoma Treatment
BY Shannon Connelly
In an interview with CURE, Evan Y. Yu, M.D., discusses the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space and the possibilities for the future treatment landscape.
Opdivo Exceeds Expectations for Lung Cancer Survival
BY Lauren M. Green
Opdivo (nivolumab) showed better long-term survival rates than expected for patients with metastatic non-small cell lung cancer (NSCLC).
Immunotherapy Drug Improves Overall Survival in Patients With Cervical Cancer
According to a phase II study, an immunotherapy targeting HPV-infected cells led to a one-year survival rate among patients with recurrent metastatic cervical cancer.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Immuno-oncology CURE discussion group.
Search Cancer Drugs & Terms